FGF21 and cardiac physiopathology
The heart is not traditionally considered either a target or a site of fibroblast growth factor-21 (FGF21) production. However, recent findings indicate that FGF21 can act as a cardiomyokine; that is, it is produced by cardiac cells at significant levels and acts in an autocrine manner on the heart...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2015-08-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fendo.2015.00133/full |
| _version_ | 1811269996345556992 |
|---|---|
| author | Anna ePlanavila Ibon eRedondo-Angulo Francesc eVillarroya |
| author_facet | Anna ePlanavila Ibon eRedondo-Angulo Francesc eVillarroya |
| author_sort | Anna ePlanavila |
| collection | DOAJ |
| description | The heart is not traditionally considered either a target or a site of fibroblast growth factor-21 (FGF21) production. However, recent findings indicate that FGF21 can act as a cardiomyokine; that is, it is produced by cardiac cells at significant levels and acts in an autocrine manner on the heart itself. The heart is sensitive to the effects of FGF21, both systemic and locally generated, owing to the expression in cardiomyocytes of β-Klotho, the key co-receptor known to confer specific responsiveness to FGF21 action. FGF21 has been demonstrated to protect against cardiac hypertrophy, cardiac inflammation, and oxidative stress. FGF21 expression in the heart is induced in response to cardiac insults, such as experimental cardiac hypertrophy and myocardial infarction in rodents, as well as in failing human hearts. Intracellular mechanisms involving PPARα and Sirt1 mediate transcriptional regulation of the FGF21 gene in response to exogenous stimuli. In humans, circulating FGF21 levels are elevated in coronary heart disease and atherosclerosis, and are associated with a higher risk of cardiovascular events in patients with type 2 diabetes. These findings provide new insights into the role of FGF21 in the heart and may offer potential therapeutic strategies for cardiac disease. |
| first_indexed | 2024-04-12T21:51:58Z |
| format | Article |
| id | doaj.art-653ee762a60d4acf98b9289b54b9fbd1 |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-04-12T21:51:58Z |
| publishDate | 2015-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-653ee762a60d4acf98b9289b54b9fbd12022-12-22T03:15:26ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922015-08-01610.3389/fendo.2015.00133159300FGF21 and cardiac physiopathologyAnna ePlanavila0Ibon eRedondo-Angulo1Francesc eVillarroya2Universitat de Barcelona and CIBER Fisiopatologia de la Obesidad y NutriciónUniversitat de Barcelona and CIBER Fisiopatologia de la Obesidad y NutriciónUniversitat de Barcelona and CIBER Fisiopatologia de la Obesidad y NutriciónThe heart is not traditionally considered either a target or a site of fibroblast growth factor-21 (FGF21) production. However, recent findings indicate that FGF21 can act as a cardiomyokine; that is, it is produced by cardiac cells at significant levels and acts in an autocrine manner on the heart itself. The heart is sensitive to the effects of FGF21, both systemic and locally generated, owing to the expression in cardiomyocytes of β-Klotho, the key co-receptor known to confer specific responsiveness to FGF21 action. FGF21 has been demonstrated to protect against cardiac hypertrophy, cardiac inflammation, and oxidative stress. FGF21 expression in the heart is induced in response to cardiac insults, such as experimental cardiac hypertrophy and myocardial infarction in rodents, as well as in failing human hearts. Intracellular mechanisms involving PPARα and Sirt1 mediate transcriptional regulation of the FGF21 gene in response to exogenous stimuli. In humans, circulating FGF21 levels are elevated in coronary heart disease and atherosclerosis, and are associated with a higher risk of cardiovascular events in patients with type 2 diabetes. These findings provide new insights into the role of FGF21 in the heart and may offer potential therapeutic strategies for cardiac disease.http://journal.frontiersin.org/Journal/10.3389/fendo.2015.00133/fullOxidative StressSirtuinscardiac hypertrophyPGC-1alphacardiac pathology |
| spellingShingle | Anna ePlanavila Ibon eRedondo-Angulo Francesc eVillarroya FGF21 and cardiac physiopathology Frontiers in Endocrinology Oxidative Stress Sirtuins cardiac hypertrophy PGC-1alpha cardiac pathology |
| title | FGF21 and cardiac physiopathology |
| title_full | FGF21 and cardiac physiopathology |
| title_fullStr | FGF21 and cardiac physiopathology |
| title_full_unstemmed | FGF21 and cardiac physiopathology |
| title_short | FGF21 and cardiac physiopathology |
| title_sort | fgf21 and cardiac physiopathology |
| topic | Oxidative Stress Sirtuins cardiac hypertrophy PGC-1alpha cardiac pathology |
| url | http://journal.frontiersin.org/Journal/10.3389/fendo.2015.00133/full |
| work_keys_str_mv | AT annaeplanavila fgf21andcardiacphysiopathology AT iboneredondoangulo fgf21andcardiacphysiopathology AT francescevillarroya fgf21andcardiacphysiopathology |